Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO

Orchestra BioMed: Nearing The First Of Two Pivotal Readouts